statnews.com·May 1, 2026
Julia Vitarello is launching a new biotech company aimed at scaling personalized genetic therapies after her previous venture, EveryONE Medicines, shut down due to regulatory challenges with the FDA. She seeks new funding to develop bespoke medicines for individuals with rare diseases, inspired by her daughter's successful treatment.
Julia Vitarello's new venture aims to scale the development of personalized genetic therapies, despite previous setbacks with EveryONE Medicines due to inadequate FDA pathways. This highlights an opportunity for investment in companies focused on overcoming regulatory hurdles to advance bespoke medicine, aligning with the increasing demand for precision medicine solutions.